FDA Approves Avlayah for Neurologic Hunter Syndrome: A Breakthrough for Rare Disease Patients

What Is Avlayah and How Does It Treat Hunter Syndrome?

Hunter syndrome, also known as Mucopolysaccharidosis type II (MPS II), is a rare X-linked recessive lysosomal storage disorder caused by a deficiency of the enzyme iduronate-2-sulfatase (I2S). Without this enzyme, complex sugars called glycosaminoglycans accumulate in cells throughout the body, causing progressive damage to the brain, heart, airways, liver, spleen, bones, and joints. The condition predominantly affects males and can present in severe or attenuated forms, with the severe form involving significant cognitive decline and neurodegeneration.

While enzyme replacement therapy with idursulfase (Elaprase) has been available since 2006 for the peripheral symptoms of MPS II, it cannot cross the blood-brain barrier effectively. Avlayah (tividenofusp alfa-eknm) was specifically designed to overcome this limitation. The drug uses a transport mechanism to shuttle the replacement enzyme across the blood-brain barrier, enabling it to reach the central nervous system and address the neurological deterioration that is often the most devastating aspect of severe Hunter syndrome.

Why Is This FDA Approval Significant for Rare Disease Treatment?

For families affected by severe Hunter syndrome, the progressive neurological decline — including loss of speech, cognitive regression, and behavioral changes — has been the most heartbreaking and untreatable aspect of the condition. Until now, standard enzyme replacement therapy could manage some of the physical symptoms such as organomegaly and joint stiffness, but did nothing to slow brain deterioration. The approval of Avlayah represents a paradigm shift, offering the first targeted treatment for the central nervous system involvement that defines the severe phenotype.

The approval also highlights broader progress in the rare disease space, where innovative drug delivery strategies are beginning to overcome the blood-brain barrier — one of the most persistent challenges in neurology. According to the FDA, the decision was based on clinical trial data demonstrating meaningful improvements in biomarkers of central nervous system disease. The regulatory pathway for Avlayah may serve as a model for future therapies targeting other lysosomal storage disorders with neurological involvement, such as Sanfilippo syndrome and metachromatic leukodystrophy.

What Should Patients and Families Know About This Treatment?

Avlayah is approved for individuals with Hunter syndrome who exhibit neurologic manifestations of the disease. As with all enzyme replacement therapies, infusion-related reactions are a potential concern, and patients will need to be monitored during and after administration. The treatment is expected to be administered in specialized centers experienced in managing lysosomal storage disorders, given the complexity of the condition and the need for ongoing multidisciplinary care.

Families of children diagnosed with MPS II should discuss the potential benefits and risks of Avlayah with their healthcare team, particularly pediatric geneticists or metabolic disease specialists. Early intervention is generally considered critical in lysosomal storage disorders, as the goal is to prevent or slow damage before it becomes irreversible. Patient advocacy organizations such as the National MPS Society can provide additional resources and support for navigating access to newly approved treatments.